The DOI matches its Crossref record; 258 of the 258 references it cites were found in a registry or an index.
Epigenetics and Colorectal Cancer Pathogenesis
Open accessAbstract
Colorectal cancer (CRC) develops through a multistage process that results from the progressive accumulation of genetic mutations, and frequently as a result of mutations in the Wnt signaling pathway. However, it has become evident over the past two decades that epigenetic alterations of the chromatin, particularly the chromatin components in the promoter regions of tumor suppressors and oncogenes, play key roles in CRC pathogenesis. Epigenetic regulation is organized at multiple levels, involving primarily DNA methylation and selective histone modifications in cancer cells. Assessment of the CRC epigenome has revealed that virtually all CRCs have aberrantly methylated genes and that the average CRC methylome has thousands of abnormally methylated genes. Although relatively less is known about the patterns of specific histone modifications in CRC, selective histone modifications and resultant chromatin conformation have been shown to act, in concert with DNA methylation, to regulate gene expression to mediate CRC pathogenesis. Moreover, it is now clear that not only DNA methylation but also histone modifications are reversible processes. The increased understanding of epigenetic regulation of gene expression in the context of CRC pathogenesis has led to development of epigenetic biomarkers for CRC diagnosis and epigenetic drugs for CRC therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–258 of 258
Mohammad, H. P., Cai, Y., McGarvey, K. M., Easwaran, H., Neste, L. V., Ohm, J. E., O’Hagan, H. M., & Baylin, S. B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0065 · Cited by 96
Mahmoudi, T., Boj, S. F., Hatzis, P., Li, V. S. W., Taouatas, N., Vries, R. G. J., Teunissen, H., Begthel, H., Korving, J., Mohammed, S., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000539 · Cited by 95
Houghton, J. A., Tillman, D. M., & Harwood, F. G. (1995) · PubMed · Cited by 93
Rare CpG Island Methylator Phenotype in Ulcerative Colitis–Associated Neoplasias
Konishi, K., Shen, L., Wang, S., Meltzer, S. J., Harpaz, N., & Issa, J. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.035 · Cited by 91
Map of differential transcript expression in the normal human large intestine
LaPointe, L. C., Dunne, R. A., Brown, G. S., Worthley, D. L., Molloy, P. L., Wattchow, D. A., & Young, G. P. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00185.2006 · Cited by 90
Global histone modification of histone H3 in colorectal cancer and its precursor lesions
Nakazawa, T., Kondo, T., Ma, D., Niu, D., Mochizuki, K., Kawasaki, T., Yamane, T., Iino, H., Fujii, H., & Katoh, R. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.07.009 · Cited by 87
Park, M. A., Reinehr, R., Häussinger, D., Voelkel‐Johnson, C., Öğretmen, B., Yacoub, A., Grant, S., & Dent, P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0274 · Cited by 87
Yang, D., Torres, C. M., Bardhan, K., Zimmerman, M. A., McGaha, T. L., & Liu, K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103035 · Cited by 86
Self-citationSugita (2010) · Oncology Reports · doi:10.3892/or.2010.1085 · Cited by 82
Fazzone, W., Wilson, P. M., LaBonte, M. J., Lenz, H., & Ladner, R. D. (2009) · International Journal of Cancer · doi:10.1002/ijc.24403 · Cited by 80
X chromosome inactivation and DNA methylation
Singer–Sam, J., & Riggs, A. D. (1993) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-9118-9_16 · Cited by 79
Common and Distinct Genomic Events in Sporadic Colorectal Cancer and Diverse Cancer Types
Martin, E. S., Tonon, G., Sinha, R., Xiao, Y., Feng, B., Kimmelman, A. C., Protopopov, A. I., Ivanova, E. V., Brennan, C., Montgomery, K. T., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2742 · Cited by 77
Tumber, A., Collins, L. S., Petersen, K. D., Thougaard, A., Christiansen, S., Dejligbjerg, M., Jensen, P. B., Sehested, M., & Ritchie, J. W. A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0374-7 · Cited by 77
Zlobec, I., Bihl, M., Foerster, A., Rufle, A., & Lugli, A. (2011) · The Journal of Pathology · doi:10.1002/path.2879 · Cited by 76
Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer
Karlsson, M., Marits, P., Dahl, K., Dagöö, T., Enerbäck, S., Thörn, M., & Winqvist, O. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0920-8 · Cited by 73
Gennaro, E. D., Bruzzese, F., Pepe, S., Leone, A., Delrio, P., Subbarayan, P. R., Avallone, A., & Budillon, A. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.9.8118 · Cited by 72
Ocker, M., Alajati, A., Ganslmayer, M., Zopf, S., L�ders, M., Neureiter, D., Hahn, E. G., Schuppan, D., & Herold, C. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0664-6 · Cited by 67
Epigenetics of colorectal cancer
Migheli, F., & Migliore, L. (2012) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01829.x · Cited by 66
Yan, H., Choi, A.-J., Lee, B., & Ting, A. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020628 · Cited by 63
McGough, J. M., Yang, D., Huang, S., Georgi, D. E., Hewitt, S. M., Röcken, C., Tänzer, M., Ebert, M. P., & Liu, K. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0280 · Cited by 62
Self-citationProspective Study of Family History and Colorectal Cancer Risk by Tumor LINE-1 Methylation Level
Ogino, S., Nishihara, R., Lochhead, P. J., Imamura, Y., Kuchiba, A., Morikawa, T., Yamauchi, M., Liao, X., Qian, Z. R., Sun, R., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs482 · Cited by 61
Ogino, S., Kawasaki, T., Kirkner, G. J., Ohnishi, M., & Fuchs, C. S. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-72 · Cited by 60
Zlobec, I., Terracciano, L., & Lugli, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0048 · Cited by 60
Unique DNA methylome profiles in CpG island methylator phenotype colon cancers
Xu, Y., Hu, B., Choi, A.-J., Gopalan, B., Lee, B., Kalady, M. F., Church, J. M., & Ting, A. H. (2011) · Genome Research · doi:10.1101/gr.122788.111 · Cited by 59
Sträter, J., Hinz, U., Hasel, C., Bhanot, U. K., Mechtersheimer, G., Lehnert, T., & Möller, P. (2005) · Gut · doi:10.1136/gut.2004.052696 · Cited by 59
Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer
Howard, J. H., Frolov, A., Tzeng, C.-W. D., Stewart, A. E., Midzak, A. S., Majmundar, A. J., Godwin, A. K., Heslin, M. J., Heslin, M. J., Bellacosa, A., et al. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.1.7469 · Cited by 58
Sobrero, A. F., Guglielmi, A., Grossi, F., Puglisi, F., & Aschele, C. (2000) · PubMed · Cited by 57
Rhee, Y.-Y., Kim, M. J., Bae, J. M., Koh, J. M., Cho, N., Juhnn, Y., Kim, D., & Kang, G. H. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2410-7 · Cited by 56
Natarajan, T. G., Kallakury, B., Sheehan, C. E., Bartlett, M. B., Ganesan, N., Preet, A., Ross, J. S., & Fitzgerald, K. T. (2010) · Cancer Cell International · doi:10.1186/1475-2867-10-13 · Cited by 56
Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients
Stratmann, J., Wang, C., Gnosa, S. P., Wallin, Å., Hinselwood, D., Sun, X., & Zhang, H. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-345 · Cited by 56
Ab, G., Leyland-Jones, B., Hg, C., Davies, B., & Df, H. (1987) · PubMed · Cited by 56
Kang, M. Y., Lee, B. B., Kim, Y., Chang, D. K., Park, S. K., Chun, H.-K., Song, S. Y., Park, J., & Kim, D. (2007) · International Journal of Cancer · doi:10.1002/ijc.22953 · Cited by 53
Ferracin, M., Gafà, R., Miotto, E., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2318 · Cited by 52
Watson, R., Muhale, F., Thorne, L. B., Yu, J., O’Neil, B. H., Hoskins, J. M., Meyers, M. O., Deal, A. M., Ibrahim, J. G., Hudson, M. L., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.011 · Cited by 51
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance
Humeniuk, R., Menon, L. G., Mishra, P. J., Gorlick, R., Sowers, R., Rode, W., Pizzorno, G., Cheng, Y.-C., Kemeny, N., Bertino, J. R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0716 · Cited by 50
Silencing of Wnt5a during colon cancer metastasis involves histone modifications
Li, Q., & Chen, H. (2012) · Epigenetics · doi:10.4161/epi.20050 · Cited by 49
Zimmerman, M. A., Rahman, N.-T., Yang, D., Lahat, G., Lazar, A. J., Pollock, R. E., Lev, D. C., & Liu, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1347 · Cited by 48
Self-citationBinder, H., Steiner, L., Przybilla, J., Rohlf, T., Prohaska, S. J., & Galle, J. (2013) · Physical Biology · doi:10.1088/1478-3975/10/2/026006 · Cited by 47
Reaction of human UMP‐CMP kinase with natural and analog substrates
Pasti, C., Gallois‐Montbrun, S., Munier‐Lehmann, H., Véron, M., Gilles, A., & Deville‐Bonne, D. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03537.x · Cited by 47
Foulds' Dangerous Idea Revisited: The Multistep Development of Tumors 40 Years Later
Klein, G. (1997) · Advances in cancer research · doi:10.1016/s0065-230x(08)60698-3 · Cited by 46
Benoit, Y. D., Laursen, K. B., Witherspoon, M., Lipkin, S. M., & Gudas, L. J. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24224 · Cited by 46
Genomic imprinting proposed as a surveillance mechanism for chromosome loss.
Thomas, J. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.480 · Cited by 44
Nagaraju, G. P., & El‐Rayes, B. F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.028 · Cited by 44
Bader, S. A., Walker, M., & Harrison, D. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603592 · Cited by 41
Yang, D., Wang, S., Brooks, C. R., Dong, Z., Schoenlein, P. V., Kumar, V., Ouyang, X., Xiong, H., Lahat, G., Hayes-Jordan, A. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2520 · Cited by 40
Self-citationNief, N., Morvan, V. L., & Robert, J. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.012 · Cited by 39
Hu, X., Zimmerman, M. A., Bardhan, K., Yang, D., Waller, J. L., Liles, G. B., Lee, J. R., Pollock, R. E., Lev, D. C., Ware, C. F., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt014 · Cited by 38
Self-citationBader, S. A., Walker, M., McQueen, H. A., Sellar, R., Oei, E., Wopereis, S., Zhu, Y., Peter, A., Bird, A. P., & Harrison, D. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206574 · Cited by 37
Sanchez, J., DeJulius, K. L., Bronner, M. P., Church, J. M., & Kalady, M. F. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21526 · Cited by 37
Tanaka, N., Huttenhower, C., Nosho, K., Baba, Y., Shima, K., Quackenbush, J. F., Haigis, K. M., Giovannucci, E. L., Fuchs, C. S., & Ogino, S. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100361 · Cited by 36
Olaru, A., Cheng, Y., Agarwal, R., Yang, J. P., David, S., Abraham, J. M., Yu, W., Kwon, J. H., Lazarev, M. G., Brant, S. R., et al. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21826 · Cited by 35
New drug therapies in peripheral T-cell lymphoma
Howman, R., & Prince, H. M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.4 · Cited by 34
McGovern, A. P., Powell, B. E., & Chevassut, T. J. T. (2012) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2012.06.018 · Cited by 32
Epigenetic reversal of acquired resistance to 5-fluorouracil treatment
Humeniuk, R., Mishra, P. J., Bertino, J. R., & Banerjee, D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0717 · Cited by 28
Wu, C. S.-Y., & Bekaii‐Saab, T. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/359041 · Cited by 27
Yu, J., Miller, C. R., Zhang, W., Sharma, M., Holtschlag, V., Watson, M. A., & McLeod, H. L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1459 · Cited by 24
Dejligbjerg, M., Grauslund, M., Christensen, I. J., Tjørnelund, J., Jensen, P. B., & Sehested, M. (2008) · Cancer Biomarkers · doi:10.3233/cbm-2008-4206 · Cited by 21
Eukaryotic Methyl-CpG-Binding Domain Proteins and Chromatin Modification
Hung, M., & Shen, C. ‐. J. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.841-846.2003 · Cited by 20
Cited by
DNA Methylation Biomarkers: Cancer and Beyond
Mikeska, T., & Craig, J. (2014) · Genes · doi:10.3390/genes5030821 · Cited by 288
Das, V., Kalita, J., & Pal, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.064 · Cited by 275
Lochhead, P., Chan, A. T., Nishihara, R., Fuchs, C. S., Beck, A. H., Giovannucci, E., & Ogino, S. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.81 · Cited by 206
Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients
Li, Y.-Y., Ge, Q.-X., Cao, J., Zhou, Y.-J., Du, Y.-L., Shen, B., Wan, Y.-J. Y., & Nie, Y.-Q. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i11.3227 · Cited by 175
Porcellini, E., Laprovitera, N., Riefolo, M., Ravaioli, M., Garajova, I., & Ferracin, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.049 · Cited by 66
Metadata
- Authors
- Bardhan, K., & Liu, K.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2013-06-05
- Volume
- 5
- Issue
- 2
- Pages
- 676-713
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2015611021
- Cited by
- 252
- References
- 258
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.